

In the Claims

Applicant has submitted a new complete claim set showing marked up claims with insertions indicated by underlining and deletions indicated by strikeouts and/or double bracketing.

1. (Withdrawn) A composition comprising soluble type I collagen, an extracellular matrix protein, and a platelet.
2. (Withdrawn) The composition of claim 1, wherein said composition further comprises plasma.
3. (Withdrawn) The composition of claim 1 or 2, wherein the extracellular matrix protein is selected from the group comprising laminin, fibronectin and entectin.
4. (Withdrawn) The composition of claim 1 or 2, wherein said composition further comprises one or more additives selected from the group comprising insoluble collagen, a growth factor, a cross-linking agent, a stem cell, a genetically altered fibroblast and a cell media supplement.
5. (Withdrawn) The composition of claim 1 or 2, wherein the soluble type I collagen is acid soluble.
6. (Withdrawn) The composition of claim 1 or 2 wherein the soluble type I collagen is basic soluble.
7. (Withdrawn) A composition comprising soluble type I collagen, a platelet and a neutralizing agent.
8. (Withdrawn) The composition of claim 7, wherein said composition further comprises plasma.

9. (Withdrawn) The composition of claim 7, wherein the neutralizing agent is sodium bicarbonate.

10. (Withdrawn) The composition of claim 7 or 8, wherein said composition further comprises one or more additives selected from the group comprising insoluble collagen, an extracellular matrix protein, a growth factor, a cross-linking agent, a stem cell, a genetically altered fibroblast and a cell media supplement.

11. (Withdrawn) A tissue-adhesive composition formulated for administration to a patient, comprising collagen, a neutralizing agent and a platelet.

12. (Withdrawn) The tissue-adhesive composition of claim 11, wherein said platelet is derived from said patient.

13. (Withdrawn) The tissue-adhesive composition of claim 11, wherein said composition further comprises plasma.

14. (Withdrawn) The tissue-adhesive composition of claim 13, wherein said plasma is derived from said patient.

15. (Withdrawn) The tissue-adhesive composition of claim 11, wherein said collagen is selected from the group comprising collagen type I, collagen type II, collagen type III, collagen type IV, collagen type V, collagen type IX and collagen type X.

16. (Withdrawn) The tissue-adhesive composition of claim 11, wherein said collagen is acid soluble type I collagen.

17. (Withdrawn) A tissue-adhesive composition formulated for administration to a patient, comprising soluble type I collagen, an extracellular matrix protein, and a platelet derived from said patient.

18. (Withdrawn) The tissue-adhesive composition of claim 17, wherein said composition further comprises plasma derived from said patient.

19. (Previously Presented) A method of treating an intra-articular injury in a subject, the method comprising: contacting the ends of a ruptured tissue from the subject with a composition comprising soluble type I collagen, a platelet, and at least one of an extracellular protein and a neutralizing agent.

20. (Previously Presented) The method of claim 19, wherein the intra-articular injury is a meniscal tear, ligament tear or a cartilage lesion.

21. (Previously Presented) The method of claim 19, further comprising mechanically joining the ends of the ruptured tissue.

22. (Withdrawn) A method of treating an extra-articular injury in a subject, the method comprising contacting the ends of a ruptured tissue from the subject with a composition comprising soluble type I collagen, a platelet, and at least one of an extracellular protein and a neutralizing agent.

23. (Withdrawn) The method of claim 22, wherein the extra-articular injury is a ligament, tendon or muscle injury.

24. (Withdrawn) The method of claim 22, further comprising mechanically joined ends of the ruptured tissue.

25. (Withdrawn) An implantable prosthesis for repairing a tissue defect in a patient comprising:

a scaffold of biologically implantable material which is amenable to cell migration, cell proliferation, and tissue production between at least two *in vivo* edges of the defect, at least a portion of the scaffold being formed of a composition comprising soluble type I collagen, a platelet, and at least one of an extracellular protein and a neutralizing agent.

26. (Withdrawn) The prosthesis of claim 25, wherein the composition includes the extracellular protein.

27. (Withdrawn) The prosthesis of claim 25, wherein the composition includes the neutralizing agent.

28. (Withdrawn) The prosthesis of claim 25, wherein the tissue defect is a tissue defect in a synovial joint.

29. (Withdrawn) The prosthesis of claim 28, wherein the tissue defect is a ruptured ligament.

30. (Withdrawn) The prosthesis of claim 28, wherein the tissue defect is a meniscal tear.

31. (Withdrawn) The prosthesis of claim 28, wherein the tissue defect is a cartilage lesion.

32. (Withdrawn) The prosthesis of claim 28, wherein the tissue defect is a ruptured rotator cuff tendon.

33. (Withdrawn) The prosthesis of claim 25, wherein said composition further comprises plasma.

34. (Withdrawn) The prosthesis of claim 33, wherein said plasma is derived from the patient.

35. (Withdrawn) The prosthesis of claim 25, wherein said platelet is derived from the patient.

36. (Withdrawn) The prosthesis of claim 25, wherein said collagen is acid soluble.
37. (Withdrawn) The prosthesis of claim 25, wherein said collagen is basic soluble.
38. (Withdrawn) The prosthesis of claim 25, wherein the composition further comprises at least one additive selected from the group comprising insoluble collage, a growth factor, a cross-linking agent, a stem cell, a genetically altered fibroblast, and a cell media supplement.

Please add new claims 39-42 as noted below.

39. (New) The method of claim 19, wherein the composition is essentially free of exogenous thrombin.
40. (New) The method of claim 19, wherein the extracellular matrix protein is selected from the group consisting of elastin, laminin, fibronectin, and entectin.
41. (New) The method of claim 19, further comprising a gene therapy agent.
42. (New) The method of claim 41, wherein the gene therapy agent includes a genetically altered cell.